相似文献
1
Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody.
Emerg Infect Dis. 2024 Aug;30(8):1668-1671. doi: 10.3201/eid3008.240019.
2
HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance.
J Clin Virol. 2011 Nov;52(3):261-4. doi: 10.1016/j.jcv.2011.07.014. Epub 2011 Aug 12.
3
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Lancet HIV. 2023 Sep;10(9):e566-e577. doi: 10.1016/S2352-3018(23)00136-4. Epub 2023 Aug 8.
4
De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.
Antivir Ther. 2011;16(4):479-87. doi: 10.3851/IMP1771.
5
Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Biol Blood Marrow Transplant. 2010 Jun;16(6):809-17. doi: 10.1016/j.bbmt.2009.12.533. Epub 2010 Jan 7.
6
Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy.
J Clin Virol. 2014 Aug;60(4):347-53. doi: 10.1016/j.jcv.2014.04.021. Epub 2014 May 4.
7
Breakthrough of hepatitis B virus escape mutants after vaccination and virus reactivation.
J Clin Virol. 2006 May;36 Suppl 1:S18-22. doi: 10.1016/s1386-6532(06)80004-1.
8
Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment.
Int J Mol Sci. 2014 Nov 21;15(11):21455-67. doi: 10.3390/ijms151121455.
9
The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C.
Antivir Ther. 2018;23(6):539-542. doi: 10.3851/IMP3259.
10
Reactivation of hepatitis B virus with mutated hepatitis B surface antigen in a liver transplant recipient receiving a graft from an antibody to hepatitis B surface antigen- and antibody to hepatitis B core antigen-positive donor.
Transfusion. 2012 Sep;52(9):1999-2006. doi: 10.1111/j.1537-2995.2011.03537.x. Epub 2012 Feb 8.
引用本文的文献
1
Use of dual antiretroviral therapy in individuals with different serological patterns for hepatitis B: What are the risks? What are the clinical implications?
HIV Med. 2025 Aug;26(8):1317-1320. doi: 10.1111/hiv.70063. Epub 2025 Jun 16.
2
To Switch or not to Switch to Long-acting Injectable Cabotegravir/Rilpivirine in PWH With Past Hepatitis B Virus (HBV) Coinfection: Which HBV Markers to Manage Risk of HBV Reactivation?
Open Forum Infect Dis. 2025 May 6;12(6):ofaf266. doi: 10.1093/ofid/ofaf266. eCollection 2025 Jun.
3
Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy.
AIDS. 2025 Aug 1;39(10):1344-1352. doi: 10.1097/QAD.0000000000004227. Epub 2025 Jul 1.
4
Acute Hepatitis B Infection in a Patient With Confirmed Immunity on Long-Acting Cabotegravir/Rilpivirine.
ACG Case Rep J. 2024 Dec 27;12(1):e01575. doi: 10.14309/crj.0000000000001575. eCollection 2025 Jan.
本文引用的文献
1
Brief Report: Hepatitis B Infection or Reactivation After Switch to 2-Drug Antiretroviral Therapy: A Case Series, Literature Review, and Management Discussion.
J Acquir Immune Defic Syndr. 2023 Oct 1;94(2):160-164. doi: 10.1097/QAI.0000000000003239.
2
Hepatitis B seroconversion revisited: new insights into the natural history of acute hepatitis B virus (HBV) infection from quantitative and highly sensitive assays and novel biomarkers.
Virol J. 2021 Nov 29;18(1):235. doi: 10.1186/s12985-021-01706-w.
3
Amino Acid Polymorphism in Hepatitis B Virus Associated With Functional Cure.
Cell Mol Gastroenterol Hepatol. 2021;12(5):1583-1598. doi: 10.1016/j.jcmgh.2021.07.013. Epub 2021 Aug 2.
4
Hepatitis B reactivation after tenofovir withdrawal in an HIV-infected patient with history of cured hepatitis B virus infection and poor immunological status.
AIDS. 2021 Aug 1;35(10):1707-1708. doi: 10.1097/QAD.0000000000002941.
5
Immune-Escape Hepatitis B Virus Mutations Associated with Viral Reactivation upon Immunosuppression.
Viruses. 2019 Aug 24;11(9):778. doi: 10.3390/v11090778.
6
HBV reactivation in allogeneic stem cell transplant recipients: Risk factors, outcome, and role of hepatitis B virus mutations.
Hepatol Commun. 2017 Nov 6;1(10):1014-1023. doi: 10.1002/hep4.1118. eCollection 2017 Dec.
7
Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study.
J Infect Dis. 2016 Jun 1;213(11):1735-42. doi: 10.1093/infdis/jiw011. Epub 2016 Jan 14.
8
A new vaccine escape mutant of hepatitis B virus causes occult infection.
Hum Vaccin Immunother. 2015;11(2):407-10. doi: 10.4161/21645515.2014.994461.
9
CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management.
MMWR Recomm Rep. 2013 Dec 20;62(RR-10):1-19.
10
Comprehensive analysis of the prevalence of hepatitis B virus escape mutations in the major hydrophilic region of surface antigen.
J Med Virol. 2012 Feb;84(2):198-206. doi: 10.1002/jmv.23183.
Zotero 插件